Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 4 min 7 sec ago

Cook Group Incorporated Promotes Barry Slowey to President of Cook Endoscopy/Cook Winston-Salem

Tue, 03/01/2016 - 13:25
BLOOMINGTON, Ind.--(Healthcare Sales & Marketing Network)--Cook Group is pleased to announce the promotion of Barry Slowey to president of Cook Endoscopy/Cook Winston-Salem. As president, Slowey will oversee the various functions in Winston-Salem, North Ca...
Devices, Personnel
Cook Medical, endoscopy, endoscope

Endocare Announces Signing Of Exclusive Agreement With R-Action Distribution

Tue, 03/01/2016 - 13:15
AUSTIN, Texas and NYON, Switzerland, March 1, 2016 -- (Healthcare Sales & Marketing Network) -- Endocare, Inc announced today the signing of an exclusive agreement with R-Action Distribution Sàrl, a subsidiary of R-Action SAS, for the distribution ...
Devices, Oncology, Distribution
R-Action Distribution, Endocare, HealthTronics, cryoablation

New Elekta iViewDose Software Designed to Provide an Essential Safety Check for Radiation Therapy

Tue, 03/01/2016 - 13:06
EPID-based in vivo patient dosimetry for error detection receives US FDA 510(k) clearance and CE Mark CRAWLEY, England, March 1, 2016 -- (Healthcare Sales & Marketing Network) -- The use of highly-focused, rapid delivery techniques such as intensity mo...
Devices, Oncology, Product Launch
Elekta, iViewDose, dosimetry, IMRT, VMAT, radiotherapy

Dentsply Sirona: Merger Creates The Dental Solutions Company(TM)

Mon, 02/29/2016 - 20:11
YORK, Pennsylvania and SALZBURG, Austria, February 29, 2016 -- (Healthcare Sales & Marketing Network) -- Dentsply Sirona Inc. (XRAY) today announced that it has successfully completed the merger of equals between DENTSPLY International Inc. ("Dentspl...
Devices, Dental, Mergers & Acquisitions
Sirona Dental, DENTSPLY, Dentsply Sirona

Allergan Announces Receipt Of FDA Acceptable For Filing Letter For Generic XIFAXAN(R) ANDA

Mon, 02/29/2016 - 20:08
DUBLIN, Feb. 29, 2016 -- (Healthcare Sales & Marketing Network) -- Allergan plc (AGN), a leading global pharmaceutical company, today announced that the Company has received an Acceptable for Filing letter from the U.S. Food and Drug Administration (FDA) ...
Biopharmaceuticals, Generics, Gastroenterology, FDA
Allergan, Valeant Pharmaceuticals, IFAXAN, rifaximin, irritable bowel syndrome

Asterias Biotherapeutics Appoints Stephen L. Cartt President and Chief Executive Officer

Mon, 02/29/2016 - 13:51
Don M. Bailey Appointed to Board of Directors and Named Chairman FREMONT, Calif., Feb. 29, 2016 -- (Healthcare Sales & Marketing Network) -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST) today announced the appointment of pharmaceutical industry veter...
Regenerative Medicine, Personnel
Asterias Biotherapeutics

Egalet Announces FDA Acceptance of New Drug Application for ARYMO(TM) ER (Morphine Sulfate) Extended-Release Tablets

Mon, 02/29/2016 - 13:43
WAYNE, Pa., Feb. 29, 2016 -- (Healthcare Sales & Marketing Network) -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for p...
Biopharmaceuticals, Drug Delivery, FDA
Egalet Corp, ARYMO ER, morphine, Guardian Technology

CHMP Issues Positive Opinion for LONSURF(R) (trifluridine/tipiracil) for Refractory Metastatic Colorectal Cancer

Mon, 02/29/2016 - 13:29
Recommendation is Based on RECOURSE Study Results Demonstrating Survival Advantage for Patients with Refractory Disease TOKYO, Feb. 29, 2016 -- (Healthcare Sales & Marketing Network) -- Taiho Pharmaceutical Co., Ltd. (Tokyo) today announced that the Co...
Biopharmaceuticals, Oncology, Regulatory
Taiho Pharmaceutical Co, LONSURF, metastatic colorectal cancer

Genentech Provides Update On Two Identical Phase III Studies Of Lebrikizumab In People With Severe Asthma

Mon, 02/29/2016 - 13:20
One study met its primary endpoint, showing lebrikizumab significantly reduced exacerbations in people with severe asthma; the second study did not meet this primary endpoint Genentech continues to evaluate these study data to better understand the resu...
Genentech, Roche Group, lebrikizumab, asthma

Galderma Delivers Innovation In Dermal Fillers With The Launch Of Two First-In-Class FDA Pivotal Phase III Trials

Fri, 02/26/2016 - 15:01
Significant R&D Investments Support Fast-growing Restylane® Silk and Restylane® Lyft Dermal Filler Brands FORT WORTH, Texas, Feb. 26, 2016 -- (Healthcare Sales & Marketing Network) -- Galderma, a global leader focused on medical solutions in sk...
Biopharmaceuticals, Dermatology
Galderma, Restylane Silk, Restylane Lyft, Dermal Filler

Lilly Receives Positive CHMP Opinion for Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis

Fri, 02/26/2016 - 13:37
INDIANAPOLIS, Feb. 26, 2016 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for ixekizu...
Biopharmaceuticals, Regulatory
Eli Lilly, ixekizumab, plaque psoriasis

Catalyst Pharmaceuticals Appoints Brian Elsbernd as Senior Vice President of Legal and Compliance

Fri, 02/26/2016 - 13:29
CORAL GABLES, Fla., Feb. 26, 2016 -- (Healthcare Sales & Marketing Network) -- Catalyst Pharmaceuticals, Inc. (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, tod...
Biopharmaceuticals, Personnel
Catalyst Pharmaceuticals

AbbVie Receives EMA Orphan Drug Designation for Investigational Compound Venetoclax for the Treatment of Acute Myeloid Leukemia (AML)

Fri, 02/26/2016 - 13:08
FDA also recently granted venetoclax Breakthrough Therapy Designation (BTD) and Orphan Drug Designation (ODD) for the treatment of patients with AML AML is the most common type of acute leukemia in adults NORTH CHICAGO, Ill., Feb. 26, 2016 -- (Health...
Biopharmaceuticals, Oncology, Regulatory
AbbVie, Orphan Drug Designation, venetoclax, acute myeloid leukemia

Valeritas Announces Leadership and Board of Directors Changes

Thu, 02/25/2016 - 20:42
John Timberlake Named as Interim CEO BRIDGEWATER, New Jersey, February 25, 2016 -- (Healthcare Sales & Marketing Network) -- Valeritas, Inc. announced today changes to its executive team this week. John Timberlake has been named the company's new Inter...
Devices, Endocrinology, Personnel
Valeritas , V-Go, Insulin Delivery device, diabetes

Sagent Pharmaceuticals Names Frank Harmon Executive Vice President Global Operations

Thu, 02/25/2016 - 20:34
Newly Created Position Supports Long-Term Growth Strategy to Expand Product Offerings and Enhance Operational Performance SCHAUMBURG, Ill., Feb. 25, 2016 -- (Healthcare Sales & Marketing Network) -- Sagent Pharmaceuticals, Inc. (SGNT), a leading provide...
Biopharmaceuticals, Personnel
Sagent Pharmaceuticals

Anthem BCBS Georgia and Virginia Contracted to Cover Cologuard as In-Network Service

Thu, 02/25/2016 - 13:45
Reimbursement for Cologuard continues expansion; will reach nearly half of Anthem's members MADISON, Wis., Feb. 25, 2016 -- (Healthcare Sales & Marketing Network) -- Exact Sciences Corp. (EXAS) today announced that under recently signed contracts, Colo...
Diagnostics, Oncology, Reimbursement
Exact Sciences, Cologuard, colorectal cancer

Accuray and GE Capital Healthcare Equipment Finance Announce Healthcare Financing Collaboration Agreement

Thu, 02/25/2016 - 13:35
New Agreement Provides Healthcare Professionals with Streamlined, Cost-Effective Options for Accessing the CyberKnife® and TomoTherapy® Systems PARIS and LONDON, February 25, 2016 -- (Healthcare Sales & Marketing Network) -- Accuray Europe and ...
Devices, Oncology
Accuray, GE Capital, CyberKnife, TomoTherapy, radiotherapy

Precision Medical Devices, Inc. Awarded Surgical Instrument Agreement With Premier, Inc.

Wed, 02/24/2016 - 16:32
NEW BRUNSWICK, N.J., Feb. 24, 2016 -- (Healthcare Sales & Marketing Network) -- Precision Medical Devices, Inc. has been awarded a group purchasing agreement for Surgical Instruments with Premier, Inc. Effective February 1, 2016, the new agreement allows ...
Devices, Surgery, Group Purchasing
Precision Medical Devices

Forty Seven Inc. Completes $75M Series A Financing and Licenses Technology from Stanford University to Advance Next Generation Immuno-Oncology Programs

Wed, 02/24/2016 - 16:25
Lead program stimulating ingestion of cancer cells by the immune system is in two Phase 1 clinical trials for solid tumors and acute myeloid leukemia (AML) PALO ALTO, Calif., Feb. 24, 2016 -- (Healthcare Sales & Marketing Network) -- Forty Seven Inc., ...
Biopharmaceuticals, Oncology, Venture Capital, Licensing
Forty Seven Inc, Hu5F9-G4, CD47 receptor

Alexza Pharmaceuticals Reacquires U.S. Commercial Rights for ADASUVE(R) (loxapine) inhalation powder

Wed, 02/24/2016 - 13:48
MOUNTAIN VIEW, Calif., Feb. 24, 2016 -- (Healthcare Sales & Marketing Network) -- Alexza Pharmaceuticals, Inc. (ALXA) announced today that it has reacquired U.S. commercial rights for ADASUVE® (loxapine) inhalation powder from Teva Pharmaceuticals USA...
Biopharmaceuticals, Acquisitions
Alexza Pharmaceuticals, Teva Pharmaceutical, ADASUVE, loxapine

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong